Mandate

Vinge advises Air Liquide Santé International on the acquisition of NordicInfu Care AB

March 11, 2013

Vinge is advising Air Liquide Santé International in connection with its acquisition of NordicInfu Care AB. Air Liquide Santé International is Europe’s leading and the world’s third largest company within home healthcare and provides treatment for patients with chronic diseases, such as Parkinson, COPD (Chronic Obstructive Pulmonary Disease) and diabetes. Air Liquide Santé International posted revenues of EUR 2.5 billion in 2012 and has 10,000 employees. Air Liquide Santé International is a division within the publicly listed French group Air Liquide.

NordicInfu Care AB is a leading company in the Nordic countries within home infusion therapy for patients with chronic diseases such as Parkinson, PAH (Pulmonary Arterial Hypertension) and diabetes and had a turnover in 2012 of approximately EUR 22 million. Through the acquisition, Air Liquide Santé International expands its home healthcare activities to the Nordic market, where presence up until now has been limited.

The Vinge team advising Air Liquide Santé International includes partner Jesper Ottergren and associate Ida Christiansson. Furthermore, among others, associates Lynn Andersson Wall and Charlotta Cronér (employment law), Rickard Vernet (competition law), Johan Cederblad (regulatory matters) and counsel Maria Schultzberg (tax) have assisted in the transaction.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026